Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 9, 2005, Pages 2235-2238

  Loh Jr , Vincent M ^a   Cockcroft, Xiao Ling ^a   Dillon, Krystyna J ^b   Dixon, Lesley ^c   Drzewiecki, Jan ^a   Eversley, Penny J ^c   Gomez, Sylvie ^a   Hoare, Janet ^c   Kerrigan, Frank ^c   Matthews, Ian T W ^a   Menear, Keith A ^a   Martin, Niall M B ^b   Newton, Roger F ^c   Paul, Jane ^c   Smith, Graeme C M ^b   Vile, Julia ^c   Whittle, Alan J ^c  

^a KuDOS Horsham Ltd   (United Kingdom)

^b KuDOS Pharmaceuticals Ltd   (United Kingdom)

^c Maybridge Plc   (United Kingdom)

Author keywords

PARP; Phthalazinone; Poly(ADP)polymerase

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG STABILITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR STABILITY; MOUSE; NONHUMAN; SUBSTITUTION REACTION;

EID: 20244389572     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.03.026     Document Type: Article

References (16)

1. D. D'Amours, S. Desnoyers, I. D'Silva, and G.G. Poirier Biochem. J. 342 1999 249 268
2. N. Ogata, K. Ueda, M. Kawaichi, and O. Hayaishi J. Biol. Chem. 256 1981 4135 4137
3. T. Lindahl, M.S. Satoh, G.G. Poirier, and A. Klungland TIBS 20 1995 405 411
4. M. Satoh, and T. Lindahl Nature 356 1992 356 358
5. A. Schlicker, P. Peschke, A. Burkle, E.W. Hahn, and J.H. Kim Int. J. Radiat. Biol. 75 1999 91 100
6. B.W. Durkacz, O. Omidiji, D.A. Gray, and S. Shall Nature 283 1980 593 596
7. S. Szabo, B. Zingarelli, M. O'Connor, and A.L. Salzman J. Clin. Invest. 100 1997 723 735
8. O. Cantoni, F. Cattbeni, V. Stocchi, R.E. Meyn, P. Cerrutti, and D. Murray Biochem. Biophys. Acta 1014 1989 1 7
9. M.R. Purnell, and W.J.D. Whish Biochem. J. 185 1980 775
10. M.J. Suto, W.R. Turner, C.M. Arundel-Suto, L.M. Werbel, and J.S. Sebolt-Leopold Anti-Cancer Drug Des. 6 1991 107 117
11. R.J. Griffin, L.C. Pemberton, D. Rhodes, C. Bleasdale, K. Bowman, A.H. Calvert, N.J. Curtin, B.W. Durkacz, D.R. Newell, J.K. Porteous, and B.T. Golding Anti-Cancer Drug Des. 10 1995 507 514
12. K.J. Dillon, G.C.M. Smith, and N.M.B. Martin J. Biomol. Screen. 8 2003 347 352
13. M. Banasik, H. Komura, M. Shimoyama, and K. Ueda J. Biol. Chem. 267 1992 1569 1575
14. Douglas, D. G.; Eversley, P. J.; Martin, N. M. B.; Newton, R. F.; Smith, G. C. M.; Vile, J.; White, C. R. Int. Patent WO 02/36576, 2002
15. A. Ruf, G.M. de Murcia, and G.E. Schulz Biochemistry 37 1998 3893 3900
16. 50 of the curve of MMS + PARP inhibitor. The cells used were HeLa B and the test compounds were used at a fixed concentration of 200 nM